中国NMPA批准礼来口服GLP-1减肥药Muyouda
China approves first oral GLP-1 weight-loss pill
中国国家药监局批准礼来口服GLP-1药物orforglipron(商品名Muyouda),用于伴有至少一种体重相关疾病(如高血压、糖尿病等)的肥胖或超重成人治疗。
原文给出NMPA批准的具体适应症与阶段,读者可据此评估同类口服GLP-1药物的竞争格局。
China has approved its first orally administered GLP-1 weight-loss drug, permitting Eli Lilly to sell its orforglipron pill in a market where 630 million adults could be overweight or obese by 2050.
GLP-1 drugs aid weight loss by mimicking a natural gut hormone that suppresses appetite and regulates blood sugar levels.
The drugs have soared in popularity in recent years, with drugmakers now competing to release pills as an alternative to existing injection treatments.
China's National Medical Products Administration (NMPA) said Thursday it had approved U.S.-based pharmaceutical giant Eli Lilly's pills, marketed as "Muyouda," to treat obese or overweight adults with at least one weight-related condition.
The American company's once-daily pills were approved in the United States in April.
It has beaten competitors such as Danish firm Novo Nordisk—which makes Wegovy—to be the first to gain approval for an oral version of the medicine in China.
GLP-1 injections from Eli Lilly, Novo Nordisk and domestic firm Innovent are already widely available in the country.
The Chinese market for weight-loss treatments is growing rapidly.
The number of obese or overweight adults in China could reach 630 million by 2050, according to a 2025 study published in The Lancet.
The country's National Health Commission has warned that 65% of the population will be obese or overweight by 2030.
Journal information: The Lancet
Who's behind this story?
Andrew Zinin
Master's in physics with research experience. Long-time science news enthusiast. Plays key role in Science X's editorial success. Full profile →
© 2026 AFP
Citation: China approves first oral GLP-1 weight-loss pill (2026, November 13) retrieved 13 November 2026 from https://medicalxpress.com/news/2026-11-china-oral-glp-weight-loss.html
This document is subject to copyright. Apart from any fair dealing for the purpose of private study or research, no part may be reproduced without the written permission. The content is provided for information purposes only.
来源:Medical Xpress · medicalxpress.com